Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a Phase 2/3 study evaluating the efficacy and safety of Pracytarabine versus regorafenib in patients with advanced hepatocellular carcinoma (HCC) who have experienced treatment failure with standard systemic therapies involving targeted drugs and immune checkpoint inhibitors, or dual immune checkpoint inhibitors.
Epistemonikos ID: a2a7260b4a5b316309a655813a6b79bd510c02fc
First added on: Dec 24, 2025